Dr. DiCarlo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Stein Plaza
Suite 420
Los Angeles, CA 90095Phone+1 310-825-5111Fax+1 310-825-7245
Summary
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2004 - 2007
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
- State University of New York Downstate Medical Center College of MedicineClass of 2001
Certifications & Licensure
- CA State Medical License 2006 - 2026
- NY State Medical License 2003 - 2008
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
Clinical Trials
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsPreclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.Jian Zhang, Nicholas P McAndrew, Xiaojia Wang, Yiqun Du, Brian DiCarlo
Breast Cancer Research. 2023-07-06 - 38 citationsPathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).Sara A. Hurvitz, Jennifer L. Caswell-Jin, Katherine McNamara, Jason J. Zoeller, Gregory R. Bean
Nature Communications. 2020-11-17 - 23 citationsPhase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastase...Sara A. Hurvitz, Rashi Singh, Brad Adams, Julie Taguchi, David Chan
Therapeutic Advances in Medical Oncology. 2018-11-09
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: